1.33
-0.03(-2.21%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.35 |
| Day High | 1.36 |
| Day Low | 1.26 |
| 52-Week High | 3.99 |
| 52-Week Low | 1.11 |
| Volume | 2.89M |
| Average Volume | 3.75M |
| Market Cap | 353.95M |
| PE | -1.53 |
| EPS | -0.87 |
| Moving Average 50 Days | 1.51 |
| Moving Average 200 Days | 1.8 |
| Change | -0.03 |
If you invested $1000 in Autolus Therapeutics plc (AUTL) since IPO date, it would be worth $53.2 as of November 08, 2025 at a share price of $1.33. Whereas If you bought $1000 worth of Autolus Therapeutics plc (AUTL) shares 5 years ago, it would be worth $116.36 as of November 08, 2025 at a share price of $1.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire Inc.
Nov 03, 2025 2:05 PM GMT
LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, annou
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
GlobeNewswire Inc.
Oct 30, 2025 11:00 AM GMT
LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today a
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
GlobeNewswire Inc.
Oct 27, 2025 11:00 AM GMT
Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal studyPreliminary efficacy data demons